A new prostate cancer drug shows promise but has limited activity in this early trial.

Patients with metastatic castration-resistant prostate cancer face a tough battle. Their cancer has spread and standard treatments no longer work. This early trial tested a new drug called EC1169. It is a small molecule that targets a specific protein on cancer cells and delivers a powerful anti-cancer agent. The team also used a matching imaging agent to see the drug at work. They compared these new tools against standard computed tomography and bone scans. The results showed the new imaging agent found more bone lesions than the old methods. This means doctors could see the disease more clearly. The drug also seemed to help patients whose cancer cells showed less activity at the start. These patients lived longer without their cancer spreading compared to others. However, the drug showed limited activity overall. This is common in early-stage research where scientists are just learning if a new approach works. Safety was not a major concern in this small group of 103 people. The study highlights the need to test both the drug and the imaging tools together in future trials. This combination could help doctors spot the disease earlier and track how well it responds to treatment.